<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320742">
  <stage>Registered</stage>
  <submitdate>9/11/2009</submitdate>
  <approvaldate>9/11/2009</approvaldate>
  <actrnumber>ACTRN12609000966291</actrnumber>
  <trial_identification>
    <studytitle>Paracetamol for low back pain</studytitle>
    <scientifictitle>In patients with acute low back pain is time contingent paracetamol, or pro re nata (PRN) paracetamol, more effective than placebo in speeding recovery from a new episode of low back pain?</scientifictitle>
    <utrn>U1111-1112-2983</utrn>
    <trialacronym>PACE</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute low back pain</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Time-contingent paracetamol: 2 tablets extended release paracetamol (665mg) 3 times daily, every 6-8 hours, spaced equally throughout the day (maximum 6 per day) until recovery or maximum 4 weeks; and PRN placebo (identical to the PRN paracetamol except for the active ingredient). 

PRN Paracetamol: 1-2 500mg paracetamol tablets every 4-6 hours as required for pain relief (maximum 8 per day) until recovery or maximum 4 weeks; and time-contingent placebo (identical to the time-contingent paracetamol except for the active ingredient).</interventions>
    <comparator>Double placebo:
Time-contingent placebo paracetamol - 2 tablets 3 times daily every 6-8 hours spaced equally throughout the day (maximum 6 per day) until recovery or maximum 4 weeks; and
PRN placebo paracetamol - 1-2 tablets every 4-6 hours as required for pain relief (maximum 8 per day) until recovery or maximum 4 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Days to recovery with recovery defined as a pain score of 0 or 1 on a 0-10 pain scale (numerical pain rating scale) that is maintained for seven consecutive days.</outcome>
      <timepoint>Measured daily from baseline until recovered.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Days to recovery with recovery defined as the first day that the participant has a pain score of 0 or 1 on a 0 to 10 numerical pain rating scale.</outcome>
      <timepoint>Measured daily from baseline until recovered.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pain score - numerical pain rating scale</outcome>
      <timepoint>Baseline, 1 week, 2 weeks, 4 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disability - Roland Morris Disability Questionnaire</outcome>
      <timepoint>Baseline, 1 week, 2 weeks, 4 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Function - Patient Specific Functional Scale</outcome>
      <timepoint>Baseline, 1 week, 2 weeks, 4 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Global Perceived Effect Scale</outcome>
      <timepoint>Baseline, 1 week, 2 weeks, 4 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subjective Sleep Quality - Item 6 Pittsburgh Sleep Quality Index</outcome>
      <timepoint>Baseline, 1 week, 2 weeks, 4 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life - Short Form 12</outcome>
      <timepoint>Baseline, 4 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Primary complaint of pain in the area between the 12th rib and buttock crease, with/without leg pain;
New episode of low back pain, preceded by a period of at least one month without low back pain;
Pain of less than 6 weeks duration;
Low back pain severe enough to cause at least moderate pain (as measured by an adaptation of item 7 of the Short Form-36).</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known or suspected serious spinal pathology;
Currently taking recommended regular doses of paracetamol;
Currenlty taking recommended regular doses of another analgesic for a pre-existing condition;
Spinal surgery within the preceding 6 months;
Currently taking psychotropic medication and whose health condition is considered to prevent reliable recording of study information;
Serious co-morbidities preventing prescription of paracetamol; 
Pregnancy or planning a pregnancy during the one-month treatment period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be enrolled by general practitioners across greater metropolitan Sydney. After determining eligibility the general practitioner will allocate the participant by handing over a sealed randomised medication pack.</concealment>
    <sequence>The randomisation schedule will be generated a priori by an independent investigator using the random number function in EXCEL.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Double-dummy placebo design</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>26/11/2009</anticipatedstartdate>
    <actualstartdate>11/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>13/11/2012</actualenddate>
    <samplesize>1650</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>The George Institute for International Health</primarysponsorname>
    <primarysponsoraddress>Level 7, 341 George St
Sydney NSW 2000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>GlaxoSmithKline</fundingname>
      <fundingaddress>Consumer Healthcare
82 Hughes Ave
Locked Bag 3
Ermington NSW 2115</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian Research Council</fundingname>
      <fundingaddress>1st Floor, 8 Brindabella Circuit
Brindabella Business Park
CANBERRA AIRPORT ACT 2609</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Associate Professor Jane Latimer</othercollaboratorname>
      <othercollaboratoraddress>The George Institute for International Health and Sydney Medical School
The University of Sydney,
NSW 2006</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Chris Maher</othercollaboratorname>
      <othercollaboratoraddress>The George Institute for International Health and Sydney Medical School 
The University of Sydney,
NSW 2006</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Andrew McLachlan</othercollaboratorname>
      <othercollaboratoraddress>Faculty of Pharmacy and Centre for Education and Research in Ageing,
Pharmacy Building (A15)
University of Sydney,
Sydney NSW 2006</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Mark Hancock</othercollaboratorname>
      <othercollaboratoraddress>Discipline of Physiotherapy
Faculty of Health Sciences, 
University of Sydney, 
PO Box 170 
Lidcombe NSW 1825</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Richard Day</othercollaboratorname>
      <othercollaboratoraddress>Clinical Pharmacology &amp; Toxicology, Therapeutics Centre, 
St Vincent's Hospital,
Darlinghurst NSW 2010</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Chris Cooper</othercollaboratorname>
      <othercollaboratoraddress>Discipline of General Practice, 
The University of Sydney
37A Booth St (C75), 
Balmain, NSW 2041</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A randomised controlled trial will be conducted of 1650 patients seeking care for recent onset low back pain. The trial will assess the effect that paracetamol has on the recovery from low back pain. Specifically, it will determine whether paracetamol shortens days to recovery from low back pain compared to placebo, and whether taking a regular dosing of paracetamol is more effective than taking an as required dosing. The trial will also measure the effect of paracetamol on disability, function, sleep quality and determine the cost-effectiveness of paracetamol for managing patients with low back pain.</summary>
    <trialwebsite>none</trialwebsite>
    <publication>none</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 6
Jane Foss Russell Building G02
The University of Sydney 
NSW 2006 AUSTRALIA</ethicaddress>
      <ethicapprovaldate>14/05/2009</ethicapprovaldate>
      <hrec>05-2009/11638</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Jane Latimer</name>
      <address>The George Institute for Global Health
Level 13, 321 Kent St Sydney NSW 2000 Australia
</address>
      <phone>+61 2 96570384</phone>
      <fax />
      <email>jlatimer@george.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Chris Williams</name>
      <address>The George Institute for Global Health
Level 13, 321 Kent St Sydney NSW 2000 Australia
</address>
      <phone>+61 2 82382412</phone>
      <fax>+61 2 85806242</fax>
      <email>cwilliams@george.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Chris Williams</name>
      <address>The George Institute for Global Health
Level 13, 321 Kent St Sydney NSW 2000 Australia
</address>
      <phone>+61 2 82382412</phone>
      <fax>+61 2 85806242</fax>
      <email>cwilliams@george.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Jane Latimer</name>
      <address>The George Institute for Global Health
Level 13, 321 Kent St Sydney NSW 2000 Australia
</address>
      <phone>+61 2 9657 0384</phone>
      <fax />
      <email>jlatimer@georgeinstitute.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>